Invitation: From July 27 to July 29, 2023, Haibu invites you to Shenzhen Ping Shan for the Shenzhen International Biomedical Industry Innovation Development Conference.
Classification:
Recent Events
Release time:
2023-09-18
Guided by the Shenzhen Municipal People's Government and hosted by the Shenzhen Pingshan District People's Government and other institutions, the '2023 Shenzhen International Biomedical Industry Innovation Development Conference' will be held from July 27 to 29, 2023, at the Grand Skylight International Hotel in Pingshan, Shenzhen.
The conference is themed 'Cross-Border Integration, Deep into the Future' and will feature a closed-door meeting for pharmaceutical leaders, a keynote forum, and nine specialized thematic forums. It will conduct in-depth discussions on topics such as the latest national pharmaceutical health industry policies, cutting-edge technologies and investments, integration of IT and BT, achievement transformation and industry-university-research cooperation, going global and internationalization, etc., promoting cross-border integration with the pioneering spirit of Shenzhen to drive breakthroughs in industrial development.
- Haibu Booth:A01, you are welcome to visit our booth for discussions.
- Conference Time:July 28-29, 2023
Beijing Haibu Pharmaceutical Technology Co., Ltd. (referred to as 'Haibu Pharmaceutical') was established in 2005 and is a high-tech enterprise with 'chemical drug research and development' as its core capability. It has a research and development center in Beijing, an active pharmaceutical ingredient (API) and formulation pilot verification center, and a GMP industrial production base. The company mainly engages in CRO services for APIs and formulations, MAH joint licensing, API-related declarations, as well as commercial supply of pharmaceutical intermediates.
It has rich experience in R&D transfer production, registration declaration of various dosage forms including chemical APIs, oral solids, liquid formulations, sterile injections, external preparations etc. The R&D products cover multiple therapeutic areas such as anti-tumor, anti-depression, anti-epilepsy, anti-anxiety, cardiovascular diseases, digestive system diseases, respiratory system diseases etc.
Haibu Pharmaceutical has been awarded the title of 'Top 20 Chinese Pharmaceutical R&D Companies' for several consecutive years and recognized as a 'Specialized & Innovative Enterprise' in Beijing; a 'National High-tech Enterprise'; a 'Beijing Science & Technology Research Development Institution'; and a 'Beijing Yizhuang Enterprise Innovation Center', among others.
Beijing Hope Pharmaceutical Co., Ltd.
